Compare Dover Corp (DOV) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Enveric Biosciences Inc — how do they compare? Dover Corp trades at $188.77 (market cap $25.45B), while Enveric Biosciences Inc trades at $1.48 (market cap $6.80M). The key difference: Dover Corp is far larger — about 3742.6× Enveric Biosciences Inc's market cap, and Dover Corp pays a 1.11% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and Enveric Biosciences Inc for 14 Days on average.
| DOV | ENVB | |
|---|---|---|
Market Cap | $25.45B | $6.80M |
Volume | 661,758 | 64,867 |
Sector | Industrials | Health |
52-Week High | $233.31 | $10.80 |
52-Week Low | $161.16 | $1.27 |
Typical Hold Time | 73 Days | 14 Days |
Enterprise Value | $26.95B | -$1.49M |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $188.29, down 1.87% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and healthy profitability (13.48% net margin, 14.98% ROE). Recent acquisitions of Cloeren and Leistung expand manufacturing capabilities, while analyst consensus remains strongly bullish with a $243.20 price target representing 29% upside potential.
The outlook remains positive given Dover's Dividend King status, strategic acquisitions, and Wall Street support. Key risks include cyclical industrial exposure and recent negative cash flow trends. With no analyst sell ratings and technical indicators suggesting potential oversold conditions, the stock presents a compelling opportunity for long-term investors despite near-term bearish technical signals.
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
